Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
WEST LAFAYETTE, Ind., May 20, 2025 (GLOBE NEWSWIRE) -- Professors from multiple Purdue locations, cross-disciplinary students and industry have all joined together with a singular focus: safer...
-
WEST LAFAYETTE, Ind., March 10, 2025 (GLOBE NEWSWIRE) -- Eradivir, a clinical-stage small molecule immunotherapy biotech company, announced it has begun a Phase 2 challenge study with its antiviral...
-
WEST LAFAYETTE, Ind., March 03, 2025 (GLOBE NEWSWIRE) -- International process systems and operation experts have launched high-tech startup Crystallization Systems Technology Inc. (CrySyst) to...
-
WEST LAFAYETTE, Ind., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Amplified Sciences, a clinical-stage life sciences diagnostic company that develops tests for early, more accurate detection of challenging...
-
WEST LAFAYETTE, Ind., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Emboa Medical Inc., a medical device startup, has mimicked a snake’s evolutionary advantage to improve the retrieval of blood clots that cause...
-
WEST LAFAYETTE, Ind., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Eradivir, a preclinical biotech company that licenses innovations from Purdue Research Foundation, has developed a patent-pending antiviral...
-
WEST LAFAYETTE, Ind., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Exposure to lead can adversely impact people’s health in several ways. A Purdue University researcher in the College of Health and Human...
-
WEST LAFAYETTE, Ind., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Eradivir, a preclinical biotech company that develops antiviral therapeutics, has completed a $10.25 million Series A funding round. The...
-
WEST LAFAYETTE, Ind., July 09, 2024 (GLOBE NEWSWIRE) -- Eradivir, a preclinical biotech company, leverages small molecule targeting technology developed in Philip Low’s lab at Purdue University to...
-
WEST LAFAYETTE, IND., July 08, 2024 (GLOBE NEWSWIRE) -- You could talk to Tillmann Kubis for hours. His laid-back demeanor and desire for everyone to understand what he’s working on is so...